ARCADIA, Calif., January 16, 2006-- StemCyte, Inc., a privately held stem cell therapy and cord blood bank, with highly accredited processing and storage facilities in both the U.S. and Taiwan, recently contributed its 250th cord blood stem cell unit for transplant. This marks another milestone in the company's rapid growth as one of the world's leading providers of quality cord blood stem cell units. StemCyte has now provided cord blood units to over 80 transplant centers worldwide across 5 continents, with the number of units released for transplantation is rapidly increasing.

Cord blood stem cell units are increasingly becoming a viable alternative to bone marrow transplants for the treatment of over 70 diseases, including leukemias, lymphomas, immune diseases and genetic disorders.

'This is an especially exciting time for the cord blood stem cell industry as now more and more transplant centers are using cord blood for both children and adult transplantations,' says StemCyte's CEO Ken Giacin. 'We are also seeing broader application far beyond leukemia. For example, StemCyte has now provided 29 cord blood stem cell units for 24 children with thalassemia, with several receiving double cord blood transplants, a very exciting and cutting edge protocol . Our concerted effort against thalassemia represents one of the largest unrelated cord blood transplant clinical efforts for this disease in the world, and our units have achieved an unprecedented 90% successful engraftment and survival rate. Similar to sickle cell anemia, thalassemia is a debilitating blood disease, which affects both the patient's quality of life and life expectancy and affects hundreds of thousands of patients a year worldwide, especially in Asia, the Middle East and the Mediterranean regions. We are extremely proud to be a leader in this life-saving effort to potentially cure these diseases.'

In addition, StemCyte's family cord blood bank and wholly-owned subsidiary, Cord Blood Family Trust™, enables families the ability to privately store their own baby's cord blood using the same laboratory, professional staff and proprietary processes as their highly accredited public bank.

'At Cord Blood Family Trust, we are extremely proud to be an important part of the StemCyte life-saving mission,' stresses Cord Blood Family Trust President and CEO Dave Dickinson about the customers' advantages of this unique connection. 'It is very difficult for other family cord blood banks to gain much transplant experience as, fortunately, the odds of a baby or their sibling needing a transplant unit in their early years is extremely low. Our customers believe that the best way to judge a family cord blood bank is to determine if their units will work in a life-saving situation, and we are learning how critical it is to work closely with a wide range of transplant centers as their protocols and methods vary. With Cord Blood Family Trust, families are now able to store their own baby's cord blood with a transplant- physician-trusted stem cell provider.'

To find out more visit StemCyte online at www.stemcyte.com or Cord Blood Family Trust at www.cordbloodfamily.com.